You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 5,403,833

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,403,833

Title:	Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof
Abstract:	This invention provides a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal a transplant rejection inhibiting amount of rapamycin. Also disclosed is a method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal (a) an amount of rapamycin in combination with (b) an amount of one or more other chemotherapeutic agents for inhibiting transplant rejection, e.g., azathioprine, corticosteroids, cyclosporin and FK506, said amounts of (a) and (b) together being effective to inhibit transplant rejection and to maintain inhibition of transplant rejection.
Inventor(s):	Calne; Sir Roy (Cambridge, GB2)
Assignee:
Application Number:	08/192,648
Patent Claims:	1. A method of inhibiting organ or tissue transplant rejection in a mammal in need thereof, comprising administering to said mammal, in combination rapamycin and a corticosteroid, said combination being administered in an amount effective to inhibit transplant rejection and including an effective amount of rapamycin and corticosteroid. 2. The method according to claim 1, wherein said rapamycin is administered in an amount comprising from about 0.5 to about 50 mg/kg/day. 3. The method according to claim 2, wherein said rapamycin is administered in an amount comprising from about 1 to about 5 mg/kg/day. 4. The method according to claim 2 wherein said rapamycin is administered in an amount comprising from about 0.5 to about 5 mg/kg/day. 5. The method according to claim 1, wherein said rapamycin is administered orally to the mammal. 6. The method according to claim 1, wherein said rapamycin is administered parenterally to the mammal. 7. The method according to claim 1, wherein said rapamycin is administered for an indefinite period of time to maintain inhibition of transplant rejection. 8. The method according to claim 7, wherein said rapamycin is administered in an amount comprising from about 0.25 to 5 mg/kg/day. 9. The method according to claim 1, wherein said rapamycin is administered in an amount comprising from about 0.25 to 50 mg/kg/day. 10. The method according to claim 1 wherein said combination is administered for between about 1 to about 180 days.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.